Summary
We have previously shown that inhaled salbutamol further increases the bronchodilator response after the maximum effect of theophylline has been obtained in patients with severe chronic bronchitis. We now report the results of adding maximally effective doses of theophylline to the maximum response obtainable from salbutamol in ten of these patients. We constructed dose response curves to ensure maximum possible effect from salbutamol. Response plateaus (in nine out of ten patients) were achieved with cumulative doses of between 200 µg and 3,000 µg salbutamol and there was a significant response (p<0.05) in every subject: the mean FVC response was 1.1 l (ranging from 0.5 to 1.8 l) and the mean FEV1 response was 0.4 l (ranging from 0.1 to 0.8 l). Theophylline, in their previously determined maximally effective doses, produced statistically significant (p<0.05) small further increases in both FVC (0.2 to 0.6 l) and FEV1 (0.1 to 0.6 l) in four patients only. The other six did not respond. In patients classified as chronic bronchitics there is clearly a wide variation in response to bronchodilators and a surprising degree of reversibility can be achieved. But because of this variation in response, conventional drug doses may be too small in some cases. Ideally, each bronchodilator should be prescribed after some form of individual dose response studies. Although this acute study shows little or no benefit in the height of the bronchodilator response the usefulness of this combination can only really be decided after similar studies including the duration of effect in long term administration.
Similar content being viewed by others
References
Barclay J, Whiting B, Meredith PA, Addis GJ (1981) Theophylline-Salbutamol Interaction: Bronchodilator response to salbutamol at maximally effective plasma theophylline concentrations. Br J Clin Pharmacol 11:203–208
Committee on the aetiology of Chronic Bronchitis of the Medical Research Council. Definition and classification of chronic bronchitis for clinical and epidemiological purposes (1965). Lancet 1:775–780
Duncan PF, Griffen JP, Solomon SS (1975) Bronchodilator drug efficacy via cyclic AMP. Thorax 30:192–196
Dyson AJ, Campbell IA (1977) Interaction between choline theophyllinate and salmefamol in patients with reversible airways obstruction. Br J Clin Pharmacol 4:677–682
Eaton ML, Green BA, Church TR, McGowan T, Niewoehner DE (1980) Efficacy of theophylline in “irreversible” airflow obstruction. Ann Intern Med 92:758–761
Gere DR, Bente HB (1977) Theophylline assay by high pressure performance liquid chromatography. Application note AN-232-3 Hewlett-Packard Company, Avondale, PA
Gribben HR, Baldwin CJ, Tattersfield AE (1979) Quantitative assessment of bronchial beta-adrenoceptor blockade in man. Br J Clin Pharmacol 7:551–556
Marlin GE, Hartnett BJS, Berend N (1978) Assessment of combined oral theophylline and inhaled beta-adrenoceptor agonist bronchodilator therapy. Br J Clin Pharmacol 5:45–50
Wagner JG (1974) A safe method for rapidly achieving plasma concentration plateaus. Clin Pharmacol Ther 6:691–700
Warrell DA, Robertson DG, Newton Howes J, Connolly ME, Paterson JW, Beilin LJ, Dollery CT (1970) Comparison of cardiorespiratory effects of isoprenaline and salbutamol in patients with bronchial asthma. Br Med J 1:65–70
Wolfe JD, Tashkin DP, Calvarese B, Simmons M (1978) Bronchodilator effects of terbutaline and aminophylline alone and in combination in asthmatic patients. N Engl J Med 298:363–367
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Barclay, J., Whiting, B. & Addis, G.J. The influence of theophylline on maximal response to salbutamol in severe chronic obstructive pulmonary disease. Eur J Clin Pharmacol 22, 389–393 (1982). https://doi.org/10.1007/BF00542540
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00542540